Relmada Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
09/05/2025 23:29
Relmada Therapeutics Inc RLMD.OQ RLMD.O is expected to show no change in quarterly revenue when it reports results on May 12 for the period ending March 31 2025 LSEG's mean analyst estimate for Relmada Therapeutics Inc is for a loss of 31 cents per share. The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Relmada Therapeutics Inc is $1.00, above its last closing price of $0.42. This summary was machine generated May 9 at 22:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million